Evidence map›Paper›PMID 41623353›Full record

ArticleJournal of human immunity2026

Autoantibodies neutralizing type 1 interferons in two cohorts of people with HIV.

Julie A Jensen, Nanna Mørk, Martin Tolstrup, Ole Søgaard, Thomas Dalhuisen, Antonio Rodriguez, Rebecca Hoh, Michael J Peluso, Steven G Deeks, Jean-Laurent Casanova and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of human immunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Autoantibodies neutralizing type I interferons underlie a third of cases of Chikungunya virus encephalitis or myelitis.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Julie A JensenDepartment of Biomedicine, Aarhus University, Aarhus, Denmark.ORCID https://orcid.org/0009-0002-9704-5442
Nanna MørkDepartment of Biomedicine, Aarhus University, Aarhus, Denmark.ORCID https://orcid.org/0009-0003-9848-3425
Martin TolstrupDepartment of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.ORCID https://orcid.org/0000-0001-7020-5173
Ole SøgaardDepartment of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.ORCID https://orcid.org/0000-0001-9107-2023
Thomas DalhuisenDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, CA, USA.ORCID https://orcid.org/0000-0001-9132-0496
Antonio RodriguezDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, CA, USA.ORCID https://orcid.org/0009-0007-7764-9640
Rebecca HohDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, CA, USA.ORCID https://orcid.org/0000-0001-5112-4220
Michael J PelusoDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, CA, USA.ORCID https://orcid.org/0000-0003-0585-6230
Steven G DeeksDivision of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, CA, USA.ORCID https://orcid.org/0000-0001-6371-747X
Jean-Laurent Casanova *Laboratory of Human Genetics of Infectious Diseases, Institut National de la Santé et de la Recherche Médicale, Necker Hospital for Sick Children, Paris, France.ORCID https://orcid.org/0000-0002-7782-4169
Trine H Mogensen *Department of Biomedicine, Aarhus University, Aarhus, Denmark.ORCID https://orcid.org/0000-0002-1853-9704

Funding

Delaney AIDS Research Enterprise to Cure HIVUM1AI164560 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS, Sharon Ruth Lewin · 2021 to 2026
$32.0M
Characterizing the virologic and immunologic signatures of HIV exceptional controlK23AI157875 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PELUSO, MICHAEL JOSEPH · 2021 to 2025
$927k
NIAID NIH HHS K23 AI157875NIAID NIH HHS UM1 AI164560
6 · The paper itself

Abstract

Autoantibodies (autoAbs) neutralizing type I interferons (IFN-I) markedly increase the risk of severe manifestations of some viral diseases. The prevalence of autoAbs neutralizing at least one IFN-I, specifically IFN-α2, IFN-β, and IFN-ω, in individuals from the Swiss human immunodeficiency virus 1 (HIV-1) cohort is largely similar to French age-matched healthy controls, with around 1% in adults by age 65 having neutralizing IFN-I autoAbs and rising thereafter. We analyzed samples from Danish individuals with HIV, including antiretroviral therapy (ART) treated (

Identifiers

PMID41623353
PMCPMC12857536

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.